Moreover, a KMT2A inhibitor combined with anti-PD-L1 or anti-PD-1 antibodies can effectively restrain the growth of a mouse model of pancreatic tumor in a Fas L- and CTL-dependent manner (49). The gene discussed is KMT2A; the disease is pancreatic neoplasm.